Clinical Trial Update: Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial of Erlotinib (an EGFR inhibitor) in metastatic EGFR-positive, triple receptor-negative breast cancer was terminated; results were posted in March…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-03-15